A New Breed Of Accelerators Helps Drive Digital Health

Many digital health start-ups require more than just capital to navigate the complicated waters of the health care industry, and a new group of seed accelerators has emerged to help meet their needs. Medtech Insight interviews Healthbox director Ateet Adhikari.

If recent investment trends are an accurate barometer, digital health care (including wireless devices and software and information technology solutions) has emerged as the new darling of early-stage health care investors. There are now a growing number of high-tech digital solutions under development to address everything from provider cost and efficiency issues to patient home-monitoring needs. The field is different than other health care segments, however, because many of the young companies seeking to enter this space are technology focused, and the principals may have little or no experience in the health care arena. As a result, these companies often require a depth of support that goes beyond what they might receive from traditional venture capital (VC) and angel funding sources. To address these needs, a new group of incubators has cropped up, known as digital health accelerators. Focused solely on the digital health technology space, these organizations fund and nurture start-up companies with promising health care technology solutions that need help navigating the complexities of the health care industry and its long list of rules, regulations, and traditions that can frustrate and hinder a young company unfamiliar with the territory.

Although health industry accelerators have been around for a while, the incubators specifically focused on digital health are bringing fresh ideas to technology start-ups developing solutions to both lower health...

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Medtech Insight for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required

More from United States

FDA Halts Acceptance Of Chinese Lab Data Due To Accuracy Issues

 
• By 

The FDA has stopped accepting data from two Chinese labs due to accuracy issues. Mid-Link and SDWH have been flagged for potentially falsified results and other misconduct. This decision, which follows months of discussions and warnings, emphasizes the FDA's commitment to ensuring data integrity in medical device submissions.

TRiCares Tricuspid Valve Replacement System Reduces Regurgitation In First-In-Human Study

 

TRiCares presented data from the first-in-human study for its tricuspid valve replacement system – Topaz – at EuroPCR 2025 on 22 May.

Guardant Health Launches Germline Hereditary Cancer Test

 

Guardant Health introduces a new germline panel test to help guide cancer treatment, assess the risk of secondary cancers in patients and identify family members at risk of cancer.

First Alzheimer’s Disease Diagnostic Blood Test Cleared By FDA

 

Fujirebio Diagnostics' Alzheimer's disease test, Lumipulse G pTau217/ß-Amyloid 1-42 Plasma Ratio, has been cleared by the US FDA.

More from North America

23andMe Purchase Will Let Regeneron Scale Drug Development

 

The consumer genomics firm will operate as a subsidiary, while Regeneron plans to leverage its database for drug discovery and trial design efforts.

Disparities — Including Financial Shortcomings — Remain In Women’s Health, Execs Say

 

FemTech leaders discussed some of the barriers that remain in unlocking the full potential of the women’s health market during SiS New York last week. They also offered solutions.

Debate On FDA User Fee Reauthorization Begins To Take Shape

 
• By 

A battle may be forming over the 2027 FDA user fee reauthorizations. At a conference Friday, Democratic Rep. Jake Auchincloss supports them for their effectiveness, while Deputy FDA Commissioner Grace Graham echoed criticisms from HHS Sec. Kennedy, among others, in calling for reform to ensure public trust.